Clinical trials: Prostatic Hyperplasia
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia
Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy
Hyponatremic hypovolemia is a frequent complication of transurethral resection of the prostate gland (TURP). Copeptin has been established as is a surrogate marker of vasopressin and is measured useful for thea clinical…
- Trial name
- NCT03912766
- Testing
- serum copeptin
- Where
- Poland
- Volunteers
- 43 people
- Sponsor
- Medical University of Lodz
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
A dual-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent following treatment with the AQUABEAM System.
- Trial name
- AHAIII (NCT04308070)
- Testing
- AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent
- Where
- India
- Volunteers
- 26 people
- Sponsor
- PROCEPT BioRobotics
BPH (Benign Prostatic Hyperplasia), HoLEP
Comparison of Convective Water Vapor Ablation (Convective Water Vapor Energy, WAVE™) With the Rezum™ System Versus Holmium Laser Enucleation of the Prostate (HoLEP) Versus Bipolar Transurethral Resection of the Prostate (TUR-P) in Patients With Benign Prostatic Syndrome (BPS) - A Randomized Study
Benign prostatic enlargement (BPH/BPS) is one of the most common benign diseases in adult men. About 50% of men are affected by the age of 50, and between the ages of 70 and 80 the prevalence rises to 70-80%.
- Conditions
- BPH (Benign Prostatic Hyperplasia), HoLEP, Rezum, TURP(Transurethral Resection of Prostate)
- Trial name
- Vektor (NCT07204002)
- Testing
- Treatment BPH
- Volunteers
- 198 people
- Sponsor
- Medical University of Graz
Benign Prostatic Hyperplasia (BPH)
Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride given for 18 months, including a 1-year double-blind randomized co-administration with either tolterodine ER or placebo in men suffering…
- Trial name
- LUTS (NCT00939120)
- Testing
- Tolterodine ER 4mg, Pre-randomization Dutasteride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Siami, Paul F., M.D.
Benign Prostatic Hyperplasia
Protocollo N 2014 - Benign Prostatic Hyperplasia
Prospective observational study on the quality of life of patients with BPH under medical therapy and/or undergoing surgery.
- Trial name
- NCT06182189
- Testing
- Observation of patients with a benign prostatic hyperplasia condition
- Where
- Italy
- Volunteers
- 8,000 people
- Sponsor
- IRCCS San Raffaele
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
Lower Urinary Tract Symptoms, Lower Urinary Tract Obstructive Syndrome
EEP in Patients With Urodynamically Proven DU/DA
The aim of this project is to create und evaluate a multicentral, retro-/prospective database for patients with urodynamically proven detrusor underactivity (DU) or acontractility (DA) secondary to a non-neurogenic aetiology, who…
- Conditions
- Lower Urinary Tract Symptoms, Lower Urinary Tract Obstructive Syndrome, Detrusor Underactivity, Detrusor Areflexia
- Trial name
- NCT06452927
- Testing
- Endoscopic enucleation of the prostate
- Volunteers
- 300 people
- Sponsor
- EEPiDuDa Study Group
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH).
- Trial name
- NCT06944145
- Testing
- raloxifene, Finasteride
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Beth Israel Deaconess Medical Center
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms
Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB).
- Trial name
- NCT07377929
- Testing
- Survey using a questionnaire.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Benaroya Research Institute
Urinary Retention
Early Removal of the Urethral Catheter Following Trans-urethral Resection of Prostate
Transurethral resection of prostate is the gold standard operation for bladder outflow obstruction due to benign prostatic enlargement. However, catheter removal day is variable.
- Trial name
- NCT04363970
- Testing
- removal of the urinary catheter
- Where
- Jordan
- Volunteers
- 200 people
- Sponsor
- University of Jordan
Benign Prostate Hyperplasia, Bladder Outlet Obstruction
En-bloc With Early Apical Release Versus Lobe-by-lobe LASER Enucleation of the Prostate
Since its introduction in 1998 , and through numerous level 1a evidence, Holmium Laser enucleation of the prostate (HoLEP) has come to be considered a size-independent golden standard treatment for management of bladder outlet…
- Trial name
- NCT07014969
- Testing
- En-bloc HoLEP
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Mansoura University
Benign Prostatic Hyperplasia
Pelvic Floor Muscle Exercise for Lower Urinary Tract Symptoms After Surgery for Benign Prostatic Hyperplasia.
This study aims to evaluate the effectiveness of pelvic floor muscle exercise (PFME) on improving lower urinary tract symptoms (LUTS), postvoid residual volume (PVR), and quality of life in patients undergoing surgery for benign…
- Trial name
- BPH LUTS PFME (NCT07293442)
- Testing
- pelvic floor muscle exercises
- Where
- 2 sites in Taiwan
- Volunteers
- 46 people
- Sponsor
- Taipei Medical University WanFang Hospital
Benign Prostatic Hyperplasia, Ejaculation
Factors Predicting The Success of Ejaculation Sparing Transurethral Resection of Prostate in Benign Prostatic Hyperplasia Patients
evaluate the factors predicting the success of ejaculation-sparing TURP in patients with BPH after surgery, in terms of voiding improvement and preserved ejaculation post-operatively.
- Trial name
- NCT07513896
- Testing
- ejaculatory preserving TURP
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Ain Shams University
Prostatic Hyperplasia
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia…
- Trial name
- NCT02244255
- Testing
- FLOMAX® capsules, Ascending doses of HYTRIN® capsules
- Volunteers
- 1,993 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate
The purpose of this ex-vivo study is to evaluate the insertion procedure for the ProstaPlant implant in human prostates and the support that it supplies to the prostate.
- Trial name
- NCT00468026
- Testing
- ProstaPlant Stent
- Where
- Israel
- Sponsor
- ProstaPlant Urology System Ltd.
Benign Prostatic Hyperplasia (BPH), Lower Urinary Track Symptoms
Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia
Lower urinary symptoms (LUTS) affect older men and their frequency and severity increase with age. According to Berry et al., the histological diagnosis of benign prostatic hyperplasia (BPH) increases from 25% in the group age…
- Trial name
- OptiZum (NCT06769997)
- Testing
- Optilume® BPH Catheter System, Rezum Water Vapor Therapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Benign Prostate Hyperplasia
Safety, Efficacy, and Short-Term Outcomes of Rezūm Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia Under Local Anesthesia With Intravenous Sedation: A Single-Center Retrospective Study of 129 Patients in the Kurdistan Region of Iraq
This single-center retrospective study evaluates the safety, feasibility, and short-term clinical outcomes of Rezūm water vapor thermal therapy (WVTT) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign…
- Trial name
- NCT07507591
- Testing
- Rezum Water Vapor Thermal Therapy
- Where
- Iraq
- Volunteers
- 129 people
- Sponsor
- ALI KAMAL M. SAMI
Benign Prostatic Hyperplasia
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
To investigate the therapeutic effect and safety of celecoxib adding on doxazosin and the potential predictive value of the absence of prostate cancer in the treatment of patients with LUTS/BPH and an elevated serum PSA level.
- Trial name
- NCT01678313
- Testing
- Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD)
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Benign Prostatic Hyperplasia
Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency
Patients presented for BPH surgery at our out patient clinic will be assessed for abnormal bleeding profile. Patients with bleeding tendency will be offered either HoLEP or Greenlight laser PVP based on prostate size cut off…
- Trial name
- NCT02293759
- Testing
- HoLEP, Greenlight laser PVP
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University